

JUN 07 2004

Sheet 1 of 2

FORM PTO-229

PATENT &amp; TRADEMARK OFFICE

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**  
(Use several sheets if necessary)

Docket Number (Optional)  
6565-66400

Application Number  
10/622,316

Applicant  
CHENG SHU CHAW ET AL.

Filing Date  
July 18, 2003

Group Art Unit  
1615

**U.S. PATENT DOCUMENTS**

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
9/1	5,430,030	Jul. 4/95	Sommer et al.	514	221	
	6,264,974	Jul. 24/01	Madhat	424	434	
	4,278,667	Jul. 14/81	Madison et al.	424	232	
	4,278,679	Jul. 14/81	Madison et al.	424	263	
	5,298,504	Mar. 29/94	Sommer et al.	514	221	
	5,939,095	Aug. 17/99	Hille et al.	424	449	
	6,114,347	Sep. 5/00	Hille et al.	514	297	
	5,480,651	Jan. 2/96	Callaway	424	464	
	6,004,582	Dec. 21/99	Faour et al.	424	473	

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
					YES	NO

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C. S. Chaw, C-W Tan, Y. Y. Yang, L. Wang and S. Moomchala. Design of physostigmine-loaded polymeric microparticles for pretreatment against exposure to organophosphate agents, Biomaterials, Volume 24, Issue 7, (2003), 1271-1277
	C Chaw, Y Yang, S Moomchala. Preparation, characterization, in vitro evaluation of physostigmine loaded POE and POE /PLGA blend sub micron spheres fabricated by spray drying, CRS conference paper, 2002
	B Zhao, S. M. Moomchala, C. S. Chaw, Y. Y. Yang. Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study, Journal of Chromatography B, 784 (2003), 323-329
	K. Tuovinen, E. Kaliste-Korhonen, F. M. Raushel, O. Hänninen, Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication, Toxicology 134 (1999) 69-178.
	S. A. Miller, D. W. Blick, S. Z. Kerenyi, M. R. Murphy, Efficacy of physostigmine as a pretreatment for organophosphate poisoning, Pharmacol. Biochem. Behav. 44 (2) (1993) 343-347.
	K. Walter, M. Muller, M. F. Barkworth, A. V. Niciecki, F. Stanislaus, Pharmacokinetics of physostigmine in man following a single application of a transdermal system, Br. J. Clin. Pharmacol. 39 (1995) 59-63.
	P. Hartvig, L. Wiklund, B. Lindstrom, Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients, Acta Anaesthesiol. Scand. 30 (1986) 177-182.
9/1	S. M. Somani, S. N. Dube, Physostigmine — an overview as pretreatment drug for organophosphate intoxication, Int. J. Clin. Pharmacol Ther Toxicol. 27 (8) (1989) 367-387.

EXAMINER:

9/1/04

DATE CONSIDERED:

2/1/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	<b>Docket Number (Optional)</b> 6565-66400	<b>Application Number</b> 10/622,316
<b>Applicant</b> CHENG SHU CHAW ET AL.		
<b>Filing Date</b> July 18, 2003		<b>Group Art Unit</b> 1615

U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>	
<div style="font-size: 2em; margin-bottom: 10px;">ON</div> <div style="font-size: 2em; margin-bottom: 10px;">I</div> <div style="font-size: 2em; margin-bottom: 10px;">I</div> <div style="font-size: 2em; margin-bottom: 10px;">I</div> <div style="font-size: 2em; margin-bottom: 10px;">I</div> <div style="font-size: 2em; margin-bottom: 10px;">V</div> <div style="font-size: 2em;">ON</div>	<p>F. Pavanetto, I. Genta, P. Giunchedi, B. Conti, Evaluation of spray drying as a method for polylactide and polylactide-co-glycolide microsphere preparation, J. Microencapsulation 10 (4) (1993) 487-497.</p> <p>M. D. L. Moretti, E. Gavini, C. Juliano, G. Pirasino, P. Giunchedi, Spray-dried microspheres containing ketoprofen formulated into capsules and tablets, J. Microencapsulation 18 (1) (2001) 111-121.</p> <p>P. O'Hara, A. J. Hickey, Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization, Pharm. Res. 17 (8) (2000) 955-961.</p> <p>B. Baras, M. A. Benoit, J. Gillard, Parameters influencing the antigen release from spray-dried poly(DL-lactide) microparticles, Int. J. Pharm. 200 (1) (2000) 133-145.</p> <p>Takada H, Uda Y, Toguchi H, Ogawa Y. Application of a spray drying technique in the production of TRH-containing sustained release microparticles of biodegradable polymers. PDA J Pharm Sci &amp; Tech 1995; 49:180-184.</p> <p>Perugini P, Genta I, Conti B, Modena T, Pavanetto F. Long-term release of clodronate from biodegradable microspheres. AAPS PharmSciTech 2001; 2(3) Article 10</p> <p>Rubnov S, Levy D, Schneider H. Liquid chromatographic analysis of physostigmine salicylate and its degradation products. J Pharm Biomed Ana 1999; 18:939-945</p>
<b>EXAMINER:</b> 	<b>DATE CONSIDERED:</b> 2/1/2006
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	